In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)

Executive Summary

Things have been bleak on the discovery side of the dealmaking world, as evidenced by a paucity of Big Pharma alliances. But the Tularik/Amgen transaction indicates a renewed interest in target-stage transactions, though with the best prospects reserved for cancer focused companies with significant chemistry capabilities.
Advertisement

Related Content

Amgen Acquires Tularik and Small-Molecule Expertise
Amgen Moves Beyond Proteins
Amgen Moves Beyond Proteins
BioVitrum/Amgen: A Sign of Early-Stage Deals to Come
BioVitrum/Amgen: A Sign of Early-Stage Deals to Come
Deal Statistics Quarterly, Q2 2003
Why Pharma Needs to Do Early-Stage Deals
The Foundations of High-Value Discovery Deals
Tularik: Unique Enough?
Tularik: Unique Enough?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel